118,% Materials and Methods
Cells. All the P815 cell clones were cultured in Petri dishes (Falcon 1001; Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, Calif.) in Dulbecco's modified Eagle's medium (Grand Island Biological Co., Grand Island, N. Y.) supplemented with 10% fetal calf serum (FCS). They were incubated at 37°C in an 8% C02 atmosphere. Ll210 cells (a DBA/2 leukemia) were grown under the same conditions.
Azaguanine-resistant Mutants. Azaguanine-resistant mutants were selected in limiting-dilution conditions in culture medium that contained 10 or 30 #g/ml of azaguanine (ICN Nutritional Biochemicals, Cleveland, Ohio). Only those mutants were used that died in a culture medium supplemented with 10 -4 M hypoxanthine (Merck AG, Darmstadt, Federal Republic of Germany), 3.8 × 10 -7 M aminopterin (ICN Nutritional Biochemicals), and 1.6 × l0 -s M 2-deoxythymidine (Merck AG) (HAT).
Spleen and Peritoneal Cells. Immune spleen cells were taken from DBA/2 mice injected intraperitoneally 23 wk earlier with living turn-P815 cells in culture medium without FCS. Control mice received the same volume of injection medium. The spleen cells were teased in Hanks' balanced salts solution supplemented with 5% FCS. Cell suspensions were filtered through a nylon-mesh gauze (80/~m; Nylon Swiss; Staniar, Manchester, England). Peritoneal cells were obtained by rinsing the peritoneal cavity with l0 ml of Hanks' balanced salts solution that contained 20 U/ml heparin (Roche, Basel, Switzerland). The cells were centrifuged for 10 min at 200 g and resuspended in RPMI-1640 medium (Grand Island Biological Co.) supplemented with 10% FCS and 10 -2 M Hepes (Sigma Chemical Co., St. Louis, Mo.).
Mixed Lymphocyte-Tumor Cell Culture
STIMULATION WITH IRRADIATED CELLS. 3 × 107 immune spleen cells were mixed with P815 cells killed by gamma irradiation (5,000 rad, Cs source). The cells were incubated in 20 ml of RPMI-1640 medium that contained 10% FCS, 10 -2 M Hepes, and 5 X 10 -6 M 2-mercaptoethanol (Merck AG) in 50-ml Falcon flasks standing upright (Falcon 3013). After 4 d of incubation at 37°C in an 8% CO2 atmosphere, the stimulated lymphocytes were washed in Hanks' balanced salts solution supplemented with 5% FCS and resuspended in RPMI-1640 medium that contained 10% FCS and 10 -2 M Hepes before assay in the SXCr-release test.
STIMULATION WITH HAT-sENSITIVE CELLS. The stimulator cells were HAT-sensitive, azaguanine-resistant mutants. The stimulation conditions were the same as above, except that the medium was supplemented with HAT as described above. The stimulator cells were killed in <2 d, whereas the survival of the lymphocytes was not affected.
Cr-retease Assays. Target cells grown in vitro were resuspended at 107 cells/ml of Hanks balanced salts solution medium supplemented with 5% FCS and incubated at 37°C with 100 #Ci/ml of Na[SlCr]O~ (Institut des Radiodl~ments, Fleurus, Belgium). 1 h later, the labeled ceils were washed first with 50 ml of Hanks' balanced salts solution medium supplemented with 5% FCS, then with 50 ml of RPMI-1640 medium that contained 10% FCS and 10 -2 M Hepes. They were resuspended in the same medium, and 50-#1 aliquots that contained 104 cells were distributed into microplates (96 wells; Linbro Chemical Co., Hamden, Conn.). Stimulated lymphocytes were added in 100 #1 of the same medium. Assays were made in triplicate. The plates were centrifuged 5 min at 100 g and incubated 4 h at 37°C in an 8% CO2 atmosphere. The plates were then centrifuged again and 75-#1 aliquots of supernate were collected and counted. The percentage of ~lCr-specific release was calculated as follows: the percent specific release = (ER -SR) X 100/(MR -SR); where ER was the observed experimental 51Cr release, SR the spontaneous release measured by incubation of 104 labeled cells in 150 #1 of RPMI-1640 medium alone, and MR the maximum release obtained by adding 50 #1 0.3% Triton X-100 (Sigma) to the target cells. The spontaneous release was = 10% of the total label incorporated into the cells.
Lytic Units. 1 lytic unit is defined here as the number of spleen or peritoneal cells that lyse 50% of 104 target cells in 4 h (9). This number was estimated from the specific release obtained at various effector to target ratios by means of the regression (1 --e-kx). The results are expressed in number of lyric units/106 cells.
Normalized Number of Lytic Units/lO n Cells. To compare the lytic activities of an effector cell on the immunizing clone (seif-lysis) and on other clones (cross-lysis), we corrected for differences IMMUNOGENIG VARIANTS OBTAINED BY MUTAGENESIS OF P815. II.
in the general sensitivity of the targets. This was done by dividing the number of lytic units obtained with a given effector on a given target by the average number of lytic units obtained on the same target with all the effectors. This average was calculated after replacement of the self-lysis value by the average number of lytic units of the relevant effector on all the other targets. The corrected values were normalized by dividing them by the average of the corrected cross-lysis values of the relevant effector.
Results
When adult DBA/2 mice were injected intraperitoneally with 2 × 105 living cells of a number of tum-variants, they completely rejected these cells in <20 d ( Table I ). After that period, these mice showed a significant protection against the immunizing variants, against other P815 turn-variants, and against the original P 1 cells that were capable of forming tumors in syngeneic mice (turn +) (13) . We tested spleen and peritoneal exudate cells of immune animals for their cytolytic activity. As demonstrated in the accompanying report (13) with immune protection experiments performed either directly or by adoptive transfer. § Clone isolated from the initial P815-X2 population, II Clones isolated from a P1 population treated with the mutagen N-methyl-N'-nit ro-N-nit rosoguanidine (13) .
Cytolytic TLymphocytes in the Peritoneal
accompanying report (13) . At this time, the peritoneal cells were collected and their cytolytic activity was tested immediately on a number of P815 tum-variants. A significant cytolysis was obtained, as shown in Table II . A fractionation by nylon column indicated that the effector cells were T lymphocytes.
As seen in Table II , the peritoneal cells immunized against variants P21 and P32 preferentially lysed the immunizing variant. A similar specificity was obtained with variants P35 and P91. None was observed with peritoneal cells immunized against P89.
Cytolysis by Immune Spleen Cells Stimulated In Vitro. Spleen cells of animals that had
been immunized and boosted so as to contain active peritoneal cells had no direct cytolytic activity. However, we observed a strong and specific cytolytic response after in vitro stimulation of immune spleen cells with the immunizing turn-clone (Table  III) . Similar results were obtained by stimulating either with turn-cells killed by irradiation or with their azaguanine-resistant, HAT-sensitive homologues in medium supplemented with HAT. The splenic effector cells were T lymphocytes, as shown by their presence in nylon-filtered population and by their inactivation with anti-Thy-1.2 serum (Table III) .
Little or no specific cytolytic activity was obtained after stimulation of spleen cells from naive animals (Table III) . Spleen cells from animals immunized 5 d earlier with living turn-cells already showed a significant specific cytolysis upon restimulation in vitro. The capacity of spleen cells to form cytolytic effector cells upon restimulation remained high between 10 d and 6 mo after immunization. A specific, but weaker, cytolysis could also be obtained with spleen cells from animals immunized with irradiated turn-variants (data not shown). (14) . ]1 Depleted from T lymphocytes by treatment with anti-Thy-l.2 (AKR anti-C3H) serum and complement.
To examine the possibility that the lytic response was directed against FCS components bound on P815 cells, we immunized mice with turn-variants grown in mouse serum for >7 d. The results were the same as those obtained after immunization with cells grown in FCS (data not shown).
Analysis of the turn-Antigenic Specificities.
To examine the pattern of singular and common antigens found on turn-variants, seven independently isolated clones were used to immunize mice and stimulate their spleen cells in vitro. The cytolytic activities were tested against these seven turn-variants and the turn ÷ clone P1 (Table IV) .
Spleen cells immunized and stimulated with P2t, P32, P35, and P91 showed a markedly preferential cytolysis for the immunizing variant, indicating the presence of Table IV , values significantly >1 indicate that the relevant target cell and the immunizing variant share an antigenic specificity that is not found on the other targets. This procedure confirmed that six out of the seven turn-variants carried a singular antigenic specificity. Furthermore, it indicated that these six antigens were all different, and that at least those strong singular antigens carried by P21, P32, P35, and P91 were completely unrelated: no significant cross-reaction above that caused by the common antigen found on the turn + cell was observed with any pair of tumvariants.
TABLZ IV

Specificities Defined by Immune Spleen Cell Cytolysis
This analysis has been extended to other tum-variants. From a total of 21 variants analyzed so far, we detected no individual antigen on 6, weak individual antigens on 4, and strong individual antigens (normalized lytic index >2) on 1 I. These turnantigens appeared to be completely unrelated to each other.
The number of stimulator cells added to the responder spleen cells affected not only the intensity of the cytolytic response, but also its specificity (Table V) . The highest and most specific cytolytic activities were observed with doses of 10s-106 stimulator cells. We checked that our failure to observe a specific antigen on P89 was not a result of the use of an improper dose of stimulator cells: no specificity was observed after stimulation at doses ranging from 3 × 10 a to 107 P89 cells/3 X 107 spleen cells (data not shown).
Absence of New Antigens on Mutagenized Cells That Have Remained Tumorigenic.
We selected 10 P815 clones whose ability to form tumors was unaffected by the mutagenic treatment (Table I) . These tum+ clones were isolated from the mutagenized population that contained turn-clones P21, P32, P35, and P91. DBA/2 mice were immunized with irradiated cells and their spleen cells were restimulated in vitro. No evidence for a singular antigen was obtained with any of these clones (Table VI) .
turn-and the turn + Antigens Are Recognized by Distinct Populations of Lymphocytes. Spleen cells recovered from mice immunized with P32, were stimulated in vitro with the same variant and assayed for their cytolytic activity against different 51Cr-labeled P815 targets in the presence of various cold competitor cells (Fig. 1) . When the target cell was the immunizing variant P32, we found that this variant was a more effective competitor than P21 or P1. When the target was another turn-or the turn + cell, we did not observe this preferential competition by P32. If there was only one population of lymphocytes with higher affinity for P32, this variant would compete better than the others against any P815 target. Therefore, immunization of DBA/2 mice with P32 generated two distinct populations of immune lymphocytes: one directed against the individual specificity of P32 and another that recognized a common antigen present on all the turn-variants and on the turn ÷ cells. Similar results were obtained with lymphocytes immunized against P21.
Discussion
We have examined the cytolytic reaction of immune syngeneic T lymphocytes against a number of independently isolated P815 turn-variants. From the 21 variants analyzed so far, 15 were found to carry new antigens that are not present on the original tum÷ cells. The presence of a strong new antigenic specificity detected by T lymphocyte-mediated cytolysis appears to be diagnostic for the turn-character: none was found on 10 clones that had remained turn + after the mutagenesis. The converse is clearly not true: some tum-variants like P89 fail to show any new antigen detectable by T cell cytolysis. The cause of the rejection of this class of turn-variants remains to be determined. An obvious possibility is an increased expression of an antigen that is already present on the P815 turn ÷ cell.
The lymphocytes immunized against each tum-variant exerted a significant cytolysis against the.other variants and against the original turn + clone, indicating the persistence on the tum-variants of an antigen present on the tum÷ cell. This is consistent with previous reports which demonstrate that P815 is capable of inducing a syngeneic cytolysis (15, 16) . Moreover, we found no instance of cross-reaction between any pair of tum-clones that could not be accounted for by this common turn + antigen. The lfi turn-variants that carry new antigens all carry different specificities. Therefore, it is probable that the number of completely independent turn-antigens that can be obtained on P815 is >30. This diversity makes it unlikely that the tum-antigens appear as a consequence of the induction of viral components by the mutagen.
For five P81fi turn-variants, it was possible to compare the pattern of specificity observed in vitro to that obtained in immune protection experiments described in the accompanying report. For variants P21, P35, and P91, specific antigens were detected both in vivo and in T cell-mediated lysis. For variant P89, no specific antigen was found either in vivo or in vitro. However, variant P32 showed no specificity in vivo, whereas it showed a definite specificity in T cell cytolysis. Thus the pattern of the specificity obtained in T cell cytolysis matches that observed in vivo very significantly, but not completely. Although this correlation favors a major role of T cytolytic cells in the rejection of most P815 tum-variants, it does not exclude other effector mechanisms. In this respect, it should be mentioned that even though teratocarcinoma and Lewis lung carcinoma tum-variants generate a very specific immune protection in vivo, we have consistently failed to obtain specific cytolytic spleen cells in mice that were immunized with these variants. (11, 12; and T. Boon, O. Kellermann, A. Van Pel, J. C. Leclerc, and J. Van Snick. Unpublished observations.). It has also been reported that, for the male-specific antigen of the mouse, the rejection of male grafts does not correlate well with the presence of cytolytic T cells (17) .
The results described here suggest that the turn-variants obtained in the P815 mastocytoma system may serve as a convenient system for the study ofT lymphocytemediated cytolysis directed against a variety of antigens on a uniform background. It will he of interest to examine the relation of the various turn-antigens with the products of the major histocompatibility locus.
Summary
Tumor cell variants that were rejected by syngeneic mice (turn-) were obtained from mastocytoma P815 by mutagenesis (as described in the accompanying report (13) . A considerable T lymphocyte-mediated lysis was observed upon incubation of these turn-variants with peritoneal exudate cells collected a few days after an intraperitoneal challenge of immune animals. Spleen cells from these animals were cytolytic after stimulation in vitro with the immunizing variant.
New antigens, absent from the original P815 turn ÷ cells, were detected on 15 of the 21 turn-variants that were tested. All these antigens appeared to be different. No new antigen was detected on any of 10 mutagenized P815 clones that had retained their ability to form tumors.
We compared the evidence obtained in vivo and in vitro for the presence of specific antigens on five turn-variants. Three variants were shown both in vivo and in vitro to carry an individual antigen. One showed no specificity either in vivo or in vitro. However, for one variant, no specificity was observed in vivo, although cytolysis tests demonstrated the existence of a singular antigenic specificity.
